Weighing approval bids from J&J, Pfizer and Roche, FDA scrutinizes data ahead of adcomm
For an upcoming FDA advisory committee meeting, the agency is questioning whether J&J, Pfizer and Roche have provided convincing clinical data for their cancer drugs in the right patient populations.
For an upcoming FDA advisory committee meeting, the agency is questioning whether J&J, Pfizer and Roche have provided convincing clinical data for their cancer drugs in the right patient populations.
